| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 10-Q | Quarterly report which provides a continuing view of a company's financial position |
Quarterly Filings
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
||
| DEF 14A | Official notification to shareholders of matters to be brought to a vote ("Proxy") |
Proxy Filings
|
||
| 10-K | Annual report which provides a comprehensive overview of the company for the past year |
Annual Filings
|
||
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 4/A | Amendment to a previously filed 4 |
3,4,5
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
